Navigation Links
Combined with BONCAT, Nanomedical Diagnostics Graphene Biosensor Identifies Circulating Biomarkers of Aging

Nanomedical Diagnostics, leading manufacturer of graphene biosensors that accelerate pharmaceutical and biotherapeutics development, announces a new publication titled, “Graphene-based Biosensor for On-Chip Detection of Bio-Orthogonally Labeled Proteins” in the journal Lab on a Chip. The paper describes Agile R100 as a “new portable digital device for biosensing… that can be employed for any click-able application.” It suggests the potential of the platform for identifying the biomarkers associated with tissue health, pathology, and aging.

While people worldwide are living longer, there is little evidence that health in later years is improving. To develop improved diagnostics and treatments for degenerative diseases, comprehensive identification of the regulators of aging is needed. Bio-orthogonal non-canonical amino acid tagging (BONCAT) is a recognized technology that metabolically labels proteins to characterize their downstream biological functions, but the technique is limited by the sample requirements, cost, complexity, and accuracy of platforms used to detect the labeled proteins.

The paper describes the development of click chemistry built on the Agile R100 graphene biosensor to rapidly detect azido-nor-leucine (ANL)-labeled proteomes in minute amounts of sample with less time and complexity than typically associated with BONCAT analysis. Mass spectrometry requires milligrams of starting material, which is challenging and costly to obtain in studies of small animals and stem cell research. Mass spectrometry is also prone to false positives due to nonspecific binding to the enrichment column and false negatives due to dilution.

“With Agile R100, we were able to detect bio-orthogonally labeled proteins with no false positives and reduced false negatives, with sample size in the sub-microgram level,” says Dr. Kiana Aran, principal investigator of the study. “The graphene biosensor has the potential to replace commercial labor-intensive optical assays and mass spectrometry, significantly reducing the sample size, complexity, cost, and time associated with BONCAT analysis.”

Agile R100 is a novel optics-free assay platform for the binding confirmation of biomolecular interactions. As a graphene biosensor, Agile R100 monitors changes in electrical conductivity to gain label-free measurements, enabling sensitive, quantitative analysis of small molecules and proteins.

About Nanomedical Diagnostics

Nanomedical Diagnostics (“Nanomed”) is a life science company based in San Diego, CA. Nanomed has developed a breakthrough electrical assay based on proprietary Field Effect Biosensing (FEB) technology that delivers sensitive label-free binding validation of biomolecular interactions for accelerated drug discovery. As the world’s leading developer and manufacturer of next-generation graphene biosensors, Nanomed’s mission is to transform the healthcare industry with innovative new products that enable cutting-edge life science research, drug discovery applications, and portable diagnostic and health monitoring platforms.

Read the full story at

Source: PRWeb
Copyright©2018 Vocus, Inc.
All rights reserved

Related biology news :

1. DERMALOG Presents the Worlds First Combined Fingerprint and Passport Scanner
2. Chitosan conduits combined with NGF microspheres repair facial nerve defects
3. Ingredient in turmeric spice when combined with anti-nausea drug kills cancer cells
4. Combined therapy could repair and prevent damage in Duchenne muscular dystrophy
5. Nanomedical Diagnostics Agile R100 Graphene Biosensor Characterizes Difficult-to-Study MYC Oncoprotein for Cancer Research
6. Fuzionaire Diagnostics Announces Disease-Agnostic Platform to Radiolabel Any Molecule for Disease Diagnosis and Drug Discovery
7. DNAnexus and QIAGEN Team Up in Education Webinar: Scaling End-to-End NGS Solutions for Clinical Diagnostics in the Cloud
8. Plum Alley Closes $1.5M in Syndicate with Women and Men Investing in CRISPR-based Diagnostics Company
9. Heart Health Innovator Boston Heart Diagnostics Joins American College of Lifestyle Medicine Corporate Roundtable
10. Singulex and Thermo Fisher Scientific Enter into License and Supply Agreement to bring Next Generation Immunodiagnostics to Sepsis and SIRS Diagnostics
11. Force Diagnostics and higi Partner to Provide Innovative Services to Life Insurance Industry:
Post Your Comments:
(Date:3/11/2019)... ... ... A new report published by the Family Equality Council reveals a strong ... aged 18 to 35 already have or are considering having children, 63% in the ... all LGBTQ prospective parents, 41% are considering assisted reproductive technology (ART) such as intrauterine ...
(Date:3/9/2019)... MURRIETA, Calif. (PRWEB) , ... March 07, 2019 , ... ... sponsor of a full day workshop presented by University of California Riverside’s ... being held from 8 a.m. to 6 p.m. on Tuesday, March 17, 2019. The ...
(Date:3/9/2019)... ... March 07, 2019 , ... StressMarq Biosciences Inc., a ... today announced the publication of its recent PCT patent application describing ... a pre-clinical stage of development, moves the company into the drug discovery field. ...
Breaking Biology News(10 mins):
(Date:2/22/2019)... (PRWEB) , ... February 20, 2019 , ... ... patents related to Novel Captcha Systems. , The patents in ... Visual patterns and tests are used to distinguish between human users and computers ...
(Date:2/14/2019)... N.J. (PRWEB) , ... February 14, 2019 , ... ... provider of helium based leak testing systems for the pharmaceutical, biotechnology and food ... the company moving forward. Brian Mulhall has been named Chief Executive ...
(Date:2/2/2019)... ... January 31, 2019 , ... The top tech companies advancing artificial ... to showcase their tools to the largest gathering of software engineers, data scientists and ... and Mathworks are partnering with the Open Data Science Conference (ODSC) to ...
(Date:2/2/2019)... ... February 01, 2019 , ... Biomatlante, a world leader ... new CEO, Julien Dert, being effective on February 1st, 2019. , Graduated from ... management, in which more than 12 years in the Medical Device industry. Chief ...
Breaking Biology Technology: